The Novel Immunosuppressant FK778 Inhibits Formation of the Immunologic Synapse
The malononitrilamide FK778 is a derivative of A77 1726, the active metabolite of the antirheumatic drug leflunomide. A77 1726 inhibits de novo pyrimidine synthesis and activity of Src-family kinases; thus, it may interfere with T-cell proliferation as well as with early T-cell signaling. Formation...
Gespeichert in:
Veröffentlicht in: | Transplantation proceedings 2005-05, Vol.37 (4), p.1970-1971 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1971 |
---|---|
container_issue | 4 |
container_start_page | 1970 |
container_title | Transplantation proceedings |
container_volume | 37 |
creator | Zeyda, M. Geyeregger, R. Poglitsch, M. Watschinger, B. Hörl, W.H. Stulnig, T.M. Säemann, M.D. |
description | The malononitrilamide FK778 is a derivative of A77 1726, the active metabolite of the antirheumatic drug leflunomide. A77 1726 inhibits de novo pyrimidine synthesis and activity of Src-family kinases; thus, it may interfere with T-cell proliferation as well as with early T-cell signaling. Formation of a stable interaction between T cells and antigen-presenting cells (APC)—the immunologic synapse—has emerged to be of crucial importance for T-cell activation. Here in we show that FK778 inhibits formation of the immunologic synapse by blocking superantigen-stimulated relocalization of adhesion (LFA-1), and signaling molecules (CD3) to the T-cell/APC contact site. These data show that FK778 affects T-cell/APC interactions, particularly events crucial for T-cell adhesion and formation of stable conjugates underlying sustained and effective T-cell activation. Thus, in this model system close to physiologic T-cell stimulation, FK778 affects critical events in the course of T-cell-mediated immune responses earlier than T-cell proliferation, which may contribute to its immunosuppressive potential. |
doi_str_mv | 10.1016/j.transproceed.2005.03.083 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67877867</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134505003192</els_id><sourcerecordid>67877867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-e49fef70acca2922c5e8ee463686ae5a544313156ebcec3f78aaf60b90cac3e53</originalsourceid><addsrcrecordid>eNqNkE1v1EAMhkcIRJeWv4AiJHpLmO8k3FDLlhUVPbScR7Neh84qyYRxUqn_vlPtinLkZFl-Xtt6GPsoeCW4sJ_31Zz8SFOKgLirJOem4qrijXrFVqKpVSmtVK_ZinMtSqG0OWHviPY891Krt-xEmFa0RooVu7m7x-JnfMC-2AzDMkZapikhkR_nYv2jrptiM96HbZipWMc0-DnEsYhdMefcIdHH3wGK28fRT4Rn7E3ne8L3x3rKfq2_3V18L69vrjYXX69L0LyZS9Rth13NPYCXrZRgsEHUVtnGejTeaK2EEsbiFhBUVzfed5ZvWw4eFBp1ys4Pe7OFPwvS7IZAgH3vR4wLOVs3-XdbZ_DLAYQUiRJ2bkph8OnRCe6edbq9-1ene9bpuHJZZw5_OF5ZtkOe_Y0e_WXg0xHwBL7v8iII9MLZ1kpudOYuDxxmJw8BkyMIOALuQkKY3S6G__nnCWZdm0o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67877867</pqid></control><display><type>article</type><title>The Novel Immunosuppressant FK778 Inhibits Formation of the Immunologic Synapse</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zeyda, M. ; Geyeregger, R. ; Poglitsch, M. ; Watschinger, B. ; Hörl, W.H. ; Stulnig, T.M. ; Säemann, M.D.</creator><creatorcontrib>Zeyda, M. ; Geyeregger, R. ; Poglitsch, M. ; Watschinger, B. ; Hörl, W.H. ; Stulnig, T.M. ; Säemann, M.D.</creatorcontrib><description>The malononitrilamide FK778 is a derivative of A77 1726, the active metabolite of the antirheumatic drug leflunomide. A77 1726 inhibits de novo pyrimidine synthesis and activity of Src-family kinases; thus, it may interfere with T-cell proliferation as well as with early T-cell signaling. Formation of a stable interaction between T cells and antigen-presenting cells (APC)—the immunologic synapse—has emerged to be of crucial importance for T-cell activation. Here in we show that FK778 inhibits formation of the immunologic synapse by blocking superantigen-stimulated relocalization of adhesion (LFA-1), and signaling molecules (CD3) to the T-cell/APC contact site. These data show that FK778 affects T-cell/APC interactions, particularly events crucial for T-cell adhesion and formation of stable conjugates underlying sustained and effective T-cell activation. Thus, in this model system close to physiologic T-cell stimulation, FK778 affects critical events in the course of T-cell-mediated immune responses earlier than T-cell proliferation, which may contribute to its immunosuppressive potential.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2005.03.083</identifier><identifier>PMID: 15919521</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Alkynes ; Biological and medical sciences ; Cell Communication - drug effects ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunosuppressive Agents - pharmacology ; Isoxazoles - pharmacology ; Lymphocyte Activation - drug effects ; Medical sciences ; Nitriles ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology ; Tissue, organ and graft immunology</subject><ispartof>Transplantation proceedings, 2005-05, Vol.37 (4), p.1970-1971</ispartof><rights>2005 Elsevier Inc.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-e49fef70acca2922c5e8ee463686ae5a544313156ebcec3f78aaf60b90cac3e53</citedby><cites>FETCH-LOGICAL-c408t-e49fef70acca2922c5e8ee463686ae5a544313156ebcec3f78aaf60b90cac3e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2005.03.083$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16962054$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15919521$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zeyda, M.</creatorcontrib><creatorcontrib>Geyeregger, R.</creatorcontrib><creatorcontrib>Poglitsch, M.</creatorcontrib><creatorcontrib>Watschinger, B.</creatorcontrib><creatorcontrib>Hörl, W.H.</creatorcontrib><creatorcontrib>Stulnig, T.M.</creatorcontrib><creatorcontrib>Säemann, M.D.</creatorcontrib><title>The Novel Immunosuppressant FK778 Inhibits Formation of the Immunologic Synapse</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>The malononitrilamide FK778 is a derivative of A77 1726, the active metabolite of the antirheumatic drug leflunomide. A77 1726 inhibits de novo pyrimidine synthesis and activity of Src-family kinases; thus, it may interfere with T-cell proliferation as well as with early T-cell signaling. Formation of a stable interaction between T cells and antigen-presenting cells (APC)—the immunologic synapse—has emerged to be of crucial importance for T-cell activation. Here in we show that FK778 inhibits formation of the immunologic synapse by blocking superantigen-stimulated relocalization of adhesion (LFA-1), and signaling molecules (CD3) to the T-cell/APC contact site. These data show that FK778 affects T-cell/APC interactions, particularly events crucial for T-cell adhesion and formation of stable conjugates underlying sustained and effective T-cell activation. Thus, in this model system close to physiologic T-cell stimulation, FK778 affects critical events in the course of T-cell-mediated immune responses earlier than T-cell proliferation, which may contribute to its immunosuppressive potential.</description><subject>Alkynes</subject><subject>Biological and medical sciences</subject><subject>Cell Communication - drug effects</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Isoxazoles - pharmacology</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Medical sciences</subject><subject>Nitriles</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><subject>Tissue, organ and graft immunology</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1v1EAMhkcIRJeWv4AiJHpLmO8k3FDLlhUVPbScR7Neh84qyYRxUqn_vlPtinLkZFl-Xtt6GPsoeCW4sJ_31Zz8SFOKgLirJOem4qrijXrFVqKpVSmtVK_ZinMtSqG0OWHviPY891Krt-xEmFa0RooVu7m7x-JnfMC-2AzDMkZapikhkR_nYv2jrptiM96HbZipWMc0-DnEsYhdMefcIdHH3wGK28fRT4Rn7E3ne8L3x3rKfq2_3V18L69vrjYXX69L0LyZS9Rth13NPYCXrZRgsEHUVtnGejTeaK2EEsbiFhBUVzfed5ZvWw4eFBp1ys4Pe7OFPwvS7IZAgH3vR4wLOVs3-XdbZ_DLAYQUiRJ2bkph8OnRCe6edbq9-1ene9bpuHJZZw5_OF5ZtkOe_Y0e_WXg0xHwBL7v8iII9MLZ1kpudOYuDxxmJw8BkyMIOALuQkKY3S6G__nnCWZdm0o</recordid><startdate>20050501</startdate><enddate>20050501</enddate><creator>Zeyda, M.</creator><creator>Geyeregger, R.</creator><creator>Poglitsch, M.</creator><creator>Watschinger, B.</creator><creator>Hörl, W.H.</creator><creator>Stulnig, T.M.</creator><creator>Säemann, M.D.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050501</creationdate><title>The Novel Immunosuppressant FK778 Inhibits Formation of the Immunologic Synapse</title><author>Zeyda, M. ; Geyeregger, R. ; Poglitsch, M. ; Watschinger, B. ; Hörl, W.H. ; Stulnig, T.M. ; Säemann, M.D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-e49fef70acca2922c5e8ee463686ae5a544313156ebcec3f78aaf60b90cac3e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Alkynes</topic><topic>Biological and medical sciences</topic><topic>Cell Communication - drug effects</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Isoxazoles - pharmacology</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Medical sciences</topic><topic>Nitriles</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><topic>Tissue, organ and graft immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zeyda, M.</creatorcontrib><creatorcontrib>Geyeregger, R.</creatorcontrib><creatorcontrib>Poglitsch, M.</creatorcontrib><creatorcontrib>Watschinger, B.</creatorcontrib><creatorcontrib>Hörl, W.H.</creatorcontrib><creatorcontrib>Stulnig, T.M.</creatorcontrib><creatorcontrib>Säemann, M.D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zeyda, M.</au><au>Geyeregger, R.</au><au>Poglitsch, M.</au><au>Watschinger, B.</au><au>Hörl, W.H.</au><au>Stulnig, T.M.</au><au>Säemann, M.D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Novel Immunosuppressant FK778 Inhibits Formation of the Immunologic Synapse</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2005-05-01</date><risdate>2005</risdate><volume>37</volume><issue>4</issue><spage>1970</spage><epage>1971</epage><pages>1970-1971</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>The malononitrilamide FK778 is a derivative of A77 1726, the active metabolite of the antirheumatic drug leflunomide. A77 1726 inhibits de novo pyrimidine synthesis and activity of Src-family kinases; thus, it may interfere with T-cell proliferation as well as with early T-cell signaling. Formation of a stable interaction between T cells and antigen-presenting cells (APC)—the immunologic synapse—has emerged to be of crucial importance for T-cell activation. Here in we show that FK778 inhibits formation of the immunologic synapse by blocking superantigen-stimulated relocalization of adhesion (LFA-1), and signaling molecules (CD3) to the T-cell/APC contact site. These data show that FK778 affects T-cell/APC interactions, particularly events crucial for T-cell adhesion and formation of stable conjugates underlying sustained and effective T-cell activation. Thus, in this model system close to physiologic T-cell stimulation, FK778 affects critical events in the course of T-cell-mediated immune responses earlier than T-cell proliferation, which may contribute to its immunosuppressive potential.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>15919521</pmid><doi>10.1016/j.transproceed.2005.03.083</doi><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1345 |
ispartof | Transplantation proceedings, 2005-05, Vol.37 (4), p.1970-1971 |
issn | 0041-1345 1873-2623 |
language | eng |
recordid | cdi_proquest_miscellaneous_67877867 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Alkynes Biological and medical sciences Cell Communication - drug effects Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunosuppressive Agents - pharmacology Isoxazoles - pharmacology Lymphocyte Activation - drug effects Medical sciences Nitriles Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases T-Lymphocytes - drug effects T-Lymphocytes - immunology Tissue, organ and graft immunology |
title | The Novel Immunosuppressant FK778 Inhibits Formation of the Immunologic Synapse |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A09%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Novel%20Immunosuppressant%20FK778%20Inhibits%20Formation%20of%20the%20Immunologic%20Synapse&rft.jtitle=Transplantation%20proceedings&rft.au=Zeyda,%20M.&rft.date=2005-05-01&rft.volume=37&rft.issue=4&rft.spage=1970&rft.epage=1971&rft.pages=1970-1971&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2005.03.083&rft_dat=%3Cproquest_cross%3E67877867%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67877867&rft_id=info:pmid/15919521&rft_els_id=S0041134505003192&rfr_iscdi=true |